Table monthly_update_prescription_drug_wac

Table: monthly_update_prescription_drug_wac_inc , manufacturer_name like N*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	gross_sales_us_dollars	gross_sales_us_dollars_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000476	Neurelis	04/22/2025	72252051002	Valtoco 10 MG Dose Nasal Liquid 10 MG/0.1ML 2 per box	01/01/2025	34.85	731.87	03/27/2029	Single Source Drug	None	None	None	1	None	1	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	04/22/2025	72252051504	Valtoco 15 MG Dose Nasal Liquid Therapy Pack 7.5 MG/0.1ML 2 per box	01/01/2025	34.85	731.87	03/27/2029	Single Source Drug	None	None	None	1	None	1	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	04/22/2025	72252052004	Valtoco 20 MG Dose Nasal Liquid Therapy Pack 10 MG/0.1ML 2 per box	01/01/2025	34.85	731.87	03/27/2029	Single Source Drug	None	None	None	1	None	1	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	04/22/2025	72252050502	Valtoco 5 MG Dose Nasal Liquid 5 MG/0.1ML 2 per box	01/01/2025	34.85	731.87	03/27/2029	Single Source Drug	None	None	None	1	None	1	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000420	Nielsen BioSciences, Inc.	01/02/2025	59584013801	Candin Injection Solution/1U in 0.1mL Intradermally/1mL Vial	01/01/2025	26.00	322.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Nielsen Biosciences price increase factors, costs and revenue constitute trade secret information and are exempt from disclosure.
Rx0000420	Nielsen BioSciences, Inc.	01/02/2025	59584014001	Spherusol Injection Solution/Coccidioides immitis Spherule-Derived Skin Test Antigen - 1.27mcg/0.1mL/1mL Vial/0.1mL Intradermally/1ml multidose vial	01/01/2025	102.00	1252.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Nielsen Biosciences price increase factors, costs and revenue constitute trade secret information and are exempt from disclosure.
Rx0000204	Noden Pharma USA, Inc.	04/30/2025	70839015030	TEKTURNA TABLETS 1 PACK 30 TABS 150 MG	01/01/2025	28.51	345.30	08/19/2026	Single Source Drug	None	None	None	1	LXO evaluates numerous elements, such as competitive market conditions, rising supply chain and operational costs, distributor and wholesaler fees, and research and development expenditures. Furthermore, the strategy takes into account the restricted size of patient populations for certain products when making pricing decisions.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000204	Noden Pharma USA, Inc.	04/30/2025	70839030030	TEKTURNA TABLETS 1 PACK 30 TABS 300 MG	01/01/2025	35.97	435.64	08/19/2026	Single Source Drug	None	None	None	1	LXO evaluates numerous elements, such as competitive market conditions, rising supply chain and operational costs, distributor and wholesaler fees, and research and development expenditures. Furthermore, the strategy takes into account the restricted size of patient populations for certain products when making pricing decisions.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000073	Novartis	04/29/2025	00078062651	AFINITOR DISPERZ TABLET FOR SUSPENSION 2 mg 28	01/14/2025	443.97	18202.78	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078062751	AFINITOR DISPERZ TABLET FOR SUSPENSION 3 mg 28	01/14/2025	448.42	18385.12	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078062851	AFINITOR DISPERZ TABLET FOR SUSPENSION 5 mg 28	01/14/2025	466.71	19135.21	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078056751	AFINITOR TABLET 10 mg 28	01/14/2025	466.71	19135.21	07/01/2028	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078059451	AFINITOR TABLET 2.5 mg 28	01/14/2025	446.20	18294.01	07/01/2028	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078056651	AFINITOR TABLET 5 mg 28	01/14/2025	466.71	19135.21	07/01/2028	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078062051	AFINITOR TABLET 7.5 mg 28	01/14/2025	466.71	19135.21	07/01/2028	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078072910	BETOPTIC S SUSPENSION, DROPS(FINAL DOSAGE FORM)(ML) 0.25 % 10	01/14/2025	36.54	405.63	None	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078072915	BETOPTIC S SUSPENSION, DROPS(FINAL DOSAGE FORM)(ML) 0.25 % 15	01/14/2025	54.81	608.40	None	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078063998	COSENTYX (2 SYRINGES) SYRINGE (ML) 150 mg/mL 1	01/14/2025	222.27	7631.23	12/21/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078063941	COSENTYX SENSOREADY (2 PENS) PEN INJECTOR (ML) 150 mg/mL 1	01/14/2025	222.27	7631.23	12/21/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078063968	COSENTYX SENSOREADY PEN PEN INJECTOR (ML) 150 mg/mL 1	01/14/2025	222.27	7631.23	12/21/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078063997	COSENTYX SYRINGE SYRINGE (ML) 150 mg/mL 1	01/14/2025	222.27	7631.23	12/21/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078105697	COSENTYX SYRINGE SYRINGE (ML) 75 mg/0.5 mL 0.5	01/14/2025	111.13	3815.61	12/21/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078056115	EXFORGE HCT TABLET 10 mg-160 mg-12.5 mg 30	01/14/2025	8.96	367.48	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078056215	EXFORGE HCT TABLET 10 mg-160 mg-25 mg 30	01/14/2025	8.96	367.48	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078056315	EXFORGE HCT TABLET 10 mg-320 mg-25 mg 30	01/14/2025	11.38	466.53	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078055915	EXFORGE HCT TABLET 5 mg-160 mg-12.5 mg 30	01/14/2025	7.90	323.96	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078056015	EXFORGE HCT TABLET 5 mg-160 mg-25 mg 30	01/14/2025	7.90	323.96	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078048915	EXFORGE TABLET 10 mg-160 mg 30	01/14/2025	8.96	367.48	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078049115	EXFORGE TABLET 10 mg-320 mg 30	01/14/2025	11.38	466.53	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078048815	EXFORGE TABLET 5 mg-160 mg 30	01/14/2025	7.90	323.96	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078049015	EXFORGE TABLET 5 mg-320 mg 30	01/14/2025	10.02	410.90	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078046815	EXJADE TABLET, DISPERSIBLE 125 mg 30	01/14/2025	37.64	1543.38	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078046915	EXJADE TABLET, DISPERSIBLE 250 mg 30	01/14/2025	75.29	3086.70	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078047015	EXJADE TABLET, DISPERSIBLE 500 mg 30	01/14/2025	150.57	6173.29	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078060715	GILENYA CAPSULE 0.5 mg 30	01/14/2025	1052.51	11683.96	12/25/2027	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078073461	ILARIS VIAL (ML) 150 mg/mL 1	01/14/2025	777.75	20221.61	12/09/2029	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078071315	JADENU SPRINKLE GRANULES IN PACKET (EA) 180 mg 30	01/14/2025	298.13	3309.54	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078072015	JADENU SPRINKLE GRANULES IN PACKET (EA) 360 mg 30	01/14/2025	596.25	6618.97	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078072715	JADENU SPRINKLE GRANULES IN PACKET (EA) 90 mg 30	01/14/2025	149.07	1654.81	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078065515	JADENU TABLET 180 mg 30	01/14/2025	298.13	3309.54	11/21/2034	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078065615	JADENU TABLET 360 mg 30	01/14/2025	596.25	6618.97	11/21/2034	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078065415	JADENU TABLET 90 mg 30	01/14/2025	149.07	1654.81	11/21/2034	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078100768	KESIMPTA PEN PEN INJECTOR (ML) 20 mg/0.4 mL 0.4	01/14/2025	611.49	9347.07	12/30/2037	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078086001	KISQALI TABLET 200 mg/day (200 mg x 1) 21	01/14/2025	565.93	7640.05	04/14/2036	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078086742	KISQALI TABLET 400 mg/day (200 mg x 2) 42	01/14/2025	1131.86	15280.15	04/14/2036	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078087463	KISQALI TABLET 600 mg/day (200 mg x 3) 63	01/14/2025	1414.83	19100.20	04/14/2036	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078116147	MEKINIST SOLUTION, RECONSTITUTED, ORAL 0.05 mg/mL 90	01/14/2025	133.83	1806.73	10/15/2030	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078110515	MEKINIST TABLET 0.5 mg 30	01/14/2025	371.76	5018.74	03/02/2034	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078111215	MEKINIST TABLET 2 mg 30	01/14/2025	1265.28	17081.33	03/02/2034	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078038566	MYFORTIC TABLET, DELAYED RELEASE (ENTERIC COATED) 180 mg 120	01/14/2025	80.62	894.94	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078038666	MYFORTIC TABLET, DELAYED RELEASE (ENTERIC COATED) 360 mg 120	01/14/2025	161.23	1789.85	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078024815	NEORAL CAPSULE 100 mg 30	01/14/2025	31.78	352.78	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078024615	NEORAL CAPSULE 25 mg 30	01/14/2025	7.95	88.28	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078027422	NEORAL SOLUTION, ORAL 100 mg/mL 50	01/14/2025	57.74	640.93	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078070184	PIQRAY TABLET 200 mg/day (200 mg x 1) 28	01/14/2025	1763.16	23802.68	04/29/2033	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078071502	PIQRAY TABLET 250 mg/day (200 mg x 1 and 50 mg x 1) 56	01/14/2025	1763.16	23802.68	04/29/2033	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078070802	PIQRAY TABLET 300 mg/day (150 mg x 2) 56	01/14/2025	1763.16	23802.68	04/29/2033	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078097261	PROMACTA POWDER IN PACKET (EA) 12.5 mg 30	01/14/2025	579.73	7826.37	01/13/2026	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078069761	PROMACTA POWDER IN PACKET (EA) 25 mg 30	01/14/2025	579.76	7826.79	01/13/2026	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068415	PROMACTA TABLET 12.5 mg 30	01/14/2025	579.73	7826.37	02/01/2028	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068515	PROMACTA TABLET 25 mg 30	01/14/2025	579.73	7826.37	02/01/2028	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068655	PROMACTA TABLET 50 mg 14	01/14/2025	489.59	6609.51	02/01/2028	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068615	PROMACTA TABLET 50 mg 30	01/14/2025	1049.13	14163.26	02/01/2028	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068715	PROMACTA TABLET 75 mg 30	01/14/2025	1573.70	21244.90	02/01/2028	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078069819	RYDAPT CAPSULE 25 mg 112	01/14/2025	2198.59	24406.60	12/02/2030	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078069899	RYDAPT CAPSULE 25 mg 56	01/14/2025	1099.30	12203.31	12/02/2030	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078109120	SCEMBLIX TABLET 20 mg 60	01/14/2025	651.41	22365.11	05/14/2040	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078109820	SCEMBLIX TABLET 40 mg 60	01/14/2025	651.41	22365.11	05/14/2040	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078070956	TABRECTA TABLET 150 mg 56	01/14/2025	284.55	11666.47	07/22/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078071656	TABRECTA TABLET 200 mg 56	01/14/2025	284.55	11666.47	07/22/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068266	TAFINLAR CAPSULE 50 mg 120	01/14/2025	904.27	12207.68	03/02/2034	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068166	TAFINLAR CAPSULE 75 mg 120	01/14/2025	1165.38	15732.65	03/02/2034	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078115421	TAFINLAR TABLET FOR SUSPENSION 10 mg 210	01/14/2025	316.51	4272.84	06/29/2038	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078059287	TASIGNA CAPSULE 150 mg 28	01/14/2025	1603.32	21644.84	10/07/2032	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078052687	TASIGNA CAPSULE 200 mg 28	01/14/2025	1603.32	21644.84	10/07/2032	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078095166	TASIGNA CAPSULE 50 mg 120	01/14/2025	1717.84	23190.81	10/07/2032	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078050883	TEGRETOL SUSPENSION, ORAL (FINAL DOSE FORM) 100 mg/5 mL 450	01/14/2025	4.85	198.82	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078050905	TEGRETOL TABLET 200 mg 100	01/14/2025	7.53	308.69	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078051005	TEGRETOL XR TABLET, EXTENDED RELEASE 12 HR 100 mg 100	01/14/2025	4.03	165.24	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078051105	TEGRETOL XR TABLET, EXTENDED RELEASE 12 HR 200 mg 100	01/14/2025	8.04	329.79	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078051205	TEGRETOL XR TABLET, EXTENDED RELEASE 12 HR 400 mg 100	01/14/2025	16.07	659.06	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078087601	TOBRADEX OINTMENT (GRAM) 0.3 %-0.1 % 3.5	01/14/2025	26.85	298.09	None	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078081301	TOBREX OINTMENT (GRAM) 0.3 % 3.5	01/14/2025	25.22	280.00	None	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078035752	TRILEPTAL SUSPENSION, ORAL (FINAL DOSE FORM) 300 mg/5 mL (60 mg/mL) 250	01/14/2025	11.95	489.75	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078045605	TRILEPTAL TABLET 150 mg 100	01/14/2025	14.20	582.14	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078033705	TRILEPTAL TABLET 300 mg 100	01/14/2025	25.93	1063.21	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078045705	TRILEPTAL TABLET 600 mg 100	01/14/2025	47.66	1954.09	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078067119	TYKERB TABLET 250 mg 150	01/14/2025	248.21	10176.70	09/18/2029	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078107766	VOTRIENT TABLET 200 mg 120	01/14/2025	434.60	17818.65	None	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078069484	ZYKADIA TABLET 150 mg 84	01/14/2025	1241.67	13783.76	02/02/2032	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drugs lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.